{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=90",
    "query": {
      "intervention": "Dose Level 3",
      "page": 90
    },
    "page_size": 10
  },
  "pagination": {
    "page": 90,
    "page_size": 10,
    "total_count": 17850,
    "total_pages": 1785,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=91&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=89&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T02:31:49.976Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00629499",
      "title": "Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2008-04",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 10,
      "location_summary": "Lakeland, Florida • St. Petersburg, Florida • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629499"
    },
    {
      "nct_id": "NCT03560232",
      "title": "Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Fracture",
        "Post-Op Wound Infection"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Ampicillin/sulbactam",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin/tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Cefazolin + Gentamicin",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin + Gentamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mercy Health Ohio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-07-09",
      "completion_date": "2020-02-19",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 2,
      "location_summary": "Warren, Ohio • Youngstown, Ohio",
      "locations": [
        {
          "city": "Warren",
          "state": "Ohio"
        },
        {
          "city": "Youngstown",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03560232"
    },
    {
      "nct_id": "NCT01839487",
      "title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2013-05-14",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839487"
    },
    {
      "nct_id": "NCT04238793",
      "title": "Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuropathic Pain From Lumbosacral Radiculopathy"
      ],
      "interventions": [
        {
          "name": "KLS-2031",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kolon Life Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-04-16",
      "completion_date": "2023-10-18",
      "has_results": false,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04238793"
    },
    {
      "nct_id": "NCT00543114",
      "title": "Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2007-10",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2016-05-27",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00543114"
    },
    {
      "nct_id": "NCT00751114",
      "title": "Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 515,
      "start_date": "2008-11",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00751114"
    },
    {
      "nct_id": "NCT00691704",
      "title": "Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide Induction",
          "type": "DRUG"
        },
        {
          "name": "Sequential Maintenance Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cristina Gasparetto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-08",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2014-08-19",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00691704"
    },
    {
      "nct_id": "NCT03328104",
      "title": "Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "2 Years to 29 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-07-24",
      "completion_date": "2023-06-29",
      "has_results": false,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03328104"
    },
    {
      "nct_id": "NCT05949684",
      "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Luspatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epoetin Alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2023-10-24",
      "completion_date": "2031-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 33,
      "location_summary": "Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05949684"
    },
    {
      "nct_id": "NCT00617552",
      "title": "Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Ileus"
      ],
      "interventions": [
        {
          "name": "5% dextrose in water",
          "type": "DRUG"
        },
        {
          "name": "TZP-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tranzyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 267,
      "start_date": "2007-07",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2012-12-07",
      "last_synced_at": "2026-11-20T02:31:49.976Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00617552"
    }
  ]
}